Resultado da Busca
1 de mai. de 2019 · Jeffrey L. Cummings, MD, ScD, joined the UNLV School of Integrated Health Sciences in 2019 as research professor within the department of brain health. Dr. Cummings is the Joy Chambers-Grundy Professor of Brain Science, an endowed professorship.
20 de abr. de 2017 · Jeffrey L. Cummings, MD, ScD, is Founding Director, Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, Nevada and Cleveland, Ohio. He is Professor of Medicine (Neurology), Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.
Articles 1–20. Cleveland Clinic Lou Ruvo Center for Brain Health - Cited by 224,649 - Alzheimer's disease.
Jeffrey Cummings, MD, ScD (HC), is the Joy Chambers-Grundy Professor of Brain Sciences, Director of the Chambers-Grundy Center for Transformative Neuroscience, Co-Director of the Pam Quirk Brain Health and Biomarker Laboratory, and Co-Director of the Alzheimer's Disease and Related Disorders (ADRD) Innovation Incubator in the Department of ...
31 de jan. de 2024 · In 2023, there were 184 trials assessing 143 drugs for the treatment of Alzheimer's disease (AD) and Mild Cognitive Impairment, with more than 60,000 participants required to populate those registered trials at 5684 sites. What is happening in 2024? Listen to Dr. Jeffrey Cummings for the insider’s overview.
Jeffrey L. Cummings, MD, ScD, joined the UNLV School of Allied Health Sciences in 2019 as a research professor within the department of Brain Health.
24 de abr. de 2024 · The goal of our annual review of the AD drug development pipeline is to note trends in the therapeutic targets, use of clinical outcome measures, role of biomarkers in clinical trials, and drug mechanisms of action (MoA) of agents being tested in current trials.
